Postpartum period

MEDITECH Expanse Unveils Labor and Delivery Solution to Nurses

Retrieved on: 
Tuesday, April 16, 2019
Technology, Other Technology, Health, Hospitals, Other Health, General Health, Midwifery, Motherhood, Women, Articles, RTT, Childbirth, Human pregnancy, Postpartum period, Medical record

Expanse Labor and Delivery, fully integrated within the MEDITECH Expanse Enterprise Health Record (EHR), helps ensure that the transition is safe and seamless from labor through postpartum care.

Key Points: 
  • Expanse Labor and Delivery, fully integrated within the MEDITECH Expanse Enterprise Health Record (EHR), helps ensure that the transition is safe and seamless from labor through postpartum care.
  • Developed to bridge any gaps between prenatal care, delivery, and postnatal care, the Expanse Labor and Delivery solution allows clinicians to review the complete patient story across the care continuum, while improving patient handoffs, mitigating patient risks, streamlining workflows tailor-made for nurses caring for maternity patients, and empowering nurses to deliver high-quality patient care.
  • Labor and Delivery Flowsheets help nurses monitor trends throughout the progression of labor, facilitate quick access to Expanse Surgical Services to conveniently document C-section delivery, and view all care documentation from prenatal care through active labor and postpartum.
  • Expanse Labor and Delivery improves the continuity of care by streamlining workflow giving valuable time back to nurses to better monitor and safely manage their patients.

Babyscripts Announces Final Agenda Featuring New Speakers for Future of Obstetrics 2019 Summit, May 5

Retrieved on: 
Tuesday, March 26, 2019
Midwifery, Human reproduction, Human pregnancy, Women's health, Motherhood, Women, Obstetrics, Gynaecology, Childbirth, Postpartum period

"To truly move the needle in women's health, we need to share, understand, and act upon innovative ideas from stakeholders across the industry."

Key Points: 
  • "To truly move the needle in women's health, we need to share, understand, and act upon innovative ideas from stakeholders across the industry."
  • Click here to learn more, see the full conference agenda and list of speakers, and to register for Future of Obstetrics.
  • Babyscripts is a new model for prenatal and postpartum care that is transforming the way expectant mothers use technology to work with their OBGYN practice.
  • It's the first mobile, clinical solution to provide remote monitoring of an obstetrician's patient population while directly improving patient satisfaction and practice reimbursement.

Postpartum Support International Statement on FDA Approval of First Treatment Indicated for Postpartum Depression

Retrieved on: 
Monday, March 25, 2019
RTT, Depression, Psychiatric diagnosis, Motherhood, Health, Women, Parenting, Midwifery, Postpartum depression, Postpartum period, Major depressive disorder, Childbirth

PORTLAND, Ore., March 25, 2019 /PRNewswire/ --On March 19, the U.S. Food and Drug Administration (FDA) approved Brexanolone, the first treatment indicated specifically for postpartum depression.

Key Points: 
  • PORTLAND, Ore., March 25, 2019 /PRNewswire/ --On March 19, the U.S. Food and Drug Administration (FDA) approved Brexanolone, the first treatment indicated specifically for postpartum depression.
  • "As the leading organization serving on the front lines advocating for women and families, Postpartum Support International (PSI) supports FDA's decision to approve this new treatment which can benefit women suffering from postpartum depression," said Ann Smith, CNM, President of PSI.
  • The new treatment will require an infusion administered in a hospital setting and is expected to be available in summerof 2019.
  • "It is important to recognize that options to treat postpartum depression (PPD) include self-help strategies, support groups, and counseling, in addition to medication.

Sage Therapeutics Announces FDA Approval of ZULRESSO™ (brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression

Retrieved on: 
Tuesday, March 19, 2019
Health, Biotechnology, Clinical trials, Mental health, Pharmaceutical, FDA, RTT, Depression, Psychiatric diagnosis, Motherhood, Women, Midwifery, Parenting, Psychiatry, Postpartum depression, Childbirth, Major depressive disorder, Postpartum period

ZULRESSO is the first and only medicine specifically approved to treat PPD, the most common medical complication of childbirth.

Key Points: 
  • ZULRESSO is the first and only medicine specifically approved to treat PPD, the most common medical complication of childbirth.
  • We are grateful for the patients, researchers, healthcare providers, advocates, caregivers and Sage employees who helped secure the approval of the first medicine specifically for postpartum depression.
  • ZULRESSO is a prescription medicine used in adults to treat a certain type of depression called Postpartum Depression.
  • ZULRESSO (brexanolone) injection is a rapidly acting GABA modulator now approved by the U.S. Food and Drug Administration as the first and only treatment specifically indicated for postpartum depression, pending DEA scheduling.

Babyscripts Announces Strategic Investment by Inova Health System

Retrieved on: 
Tuesday, March 19, 2019
Women's health, Human reproduction, Midwifery, RTT, Women, Human pregnancy, Motherhood, Inova Health System, Pregnancy, Postpartum period, Childbirth, Obstetrics

WASHINGTON, March 19, 2019 /PRNewswire-PRWeb/ -- Babyscripts, Inc. , the leading virtual care platform for managing obstetrics, is excited to announce a strategic partnership with Inova Health System, the region's leading not-for-profit healthcare provider.

Key Points: 
  • WASHINGTON, March 19, 2019 /PRNewswire-PRWeb/ -- Babyscripts, Inc. , the leading virtual care platform for managing obstetrics, is excited to announce a strategic partnership with Inova Health System, the region's leading not-for-profit healthcare provider.
  • In concert with a $500K investment, Inova will partner with Babyscripts to deploy the market's most extensive, clinically-validated virtual care obstetrics platform; and support holistic care for mothers in pregnancy and postpartum.
  • Aligned with their investment, Inova will deploy the Babyscripts' solution first to their employee health plan through Innovation Health, and then to their entire system.
  • Inova will use Babyscripts to engage women continually through their pregnancy and postpartum with digital tools, which will also reduce risk across the population.

Babyscripts Announces Strategic Partnership with Penn Medicine to Improve Postpartum Health

Retrieved on: 
Tuesday, February 26, 2019
Midwifery, Women, Motherhood, Parenting, RTT, Women's health, Childbirth, Postpartum period

WASHINGTON, Feb. 26, 2019 /PRNewswire-PRWeb/ -- Babyscripts, Inc. , the leading virtual care platform for managing obstetrics, announced today that they are entering into a strategic partnership with Penn Medicine, one of the world's leading academic medical centers, to improve postpartum health.

Key Points: 
  • WASHINGTON, Feb. 26, 2019 /PRNewswire-PRWeb/ -- Babyscripts, Inc. , the leading virtual care platform for managing obstetrics, announced today that they are entering into a strategic partnership with Penn Medicine, one of the world's leading academic medical centers, to improve postpartum health.
  • This partnership will pair Babyscripts' remote monitoring technology with the knowledge gained from Penn Medicine's Heart Safe Motherhood program (HSM) to improve the quality of postpartum care while lowering costs.
  • "We are incredibly excited to partner with Penn Medicine to improve the management of patients after they deliver," says Juan Pablo Segura, President and co-founder of Babyscripts.
  • We are eager to partner with Babyscripts to build on our experience to improve health outcomes for mothers," says Srinivas.

New Study Shows Supplementation with Nicotinamide Riboside (NR) During Breastfeeding Yields Measurable, Lasting Benefits to Mothers and Offspring in Animal Model

Retrieved on: 
Wednesday, January 23, 2019
Women, Health, Biotechnology, Clinical trials, Genetics, Pharmaceutical, Baby, Maternity, Parenting, Communications, Research, Public relations, Investor relations, FDA, Consumer, Science, General Health, Midwifery, Women, Articles, Motherhood, RTT, Human pregnancy, Infant feeding, Weaning, Postpartum period, Childbirth

The preclinical study was designed to test the hypothesis that postpartum might disrupt maternal NAD levels and that supplementation with NR might benefit mothers and their offspring.

Key Points: 
  • The preclinical study was designed to test the hypothesis that postpartum might disrupt maternal NAD levels and that supplementation with NR might benefit mothers and their offspring.
  • This study, conducted in mice and rats, is the first to measure postpartum NAD levels and the effects of NR supplementation during this time.
  • While the researchers only fed NR to the rodent mothers, this maternal supplementation led to lasting benefits for their offspring.
  • The offspring of NR supplemented mothers showed greater coordination, strength, and capacity for learning even weeks after being weaned from their mothers.

Heart Remodeling During Pregnancy and the Early Postpartum Period

Retrieved on: 
Tuesday, January 22, 2019
RTT, Women's health, Human reproduction, Midwifery, Women, Motherhood, Cardiomyopathy, Peripartum cardiomyopathy, Childbirth, Postpartum period, Pregnancy, Dilated cardiomyopathy

The enlarged heart subsequently remodels to the nonpregnant state with time in the postpartum period.

Key Points: 
  • The enlarged heart subsequently remodels to the nonpregnant state with time in the postpartum period.
  • About 1 in 1000 women will have trouble remodeling the heart in late pregnancy or the postpartum period, where the heart remains dilated and becomes weak giving rise to a condition called peripartum cardiomyopathy.
  • Understanding the molecular, structural and functional changes that naturally occur in the heart during pregnancy and the early postpartum period will be helpful in managing peripartum cardiomyopathy.
  • Dr. LaVoie said "Changes in the heart during pregnancy are gradual and peak at late pregnancy, while changes in the early postpartum period are more dramatic.

Survey: Misconceptions Regarding Postpartum Depression Persist Despite Increased Exposure and Discussion

Retrieved on: 
Monday, January 7, 2019
Women, Health, Mental health, Baby, Maternity, Parenting, Consumer, Family, General Health, RTT, Psychiatric diagnosis, Depression, Motherhood, Parenting, Midwifery, Psychiatry, Health, Postpartum depression, Postpartum period, Childbirth, Mood disorder

A survey on postpartum depression was evenly distributed across the country to more than 200 women.

Key Points: 
  • A survey on postpartum depression was evenly distributed across the country to more than 200 women.
  • Respondents anonymously answered questions regarding the effects of postpartum depression on women, their babies, and family.
  • Kelsey-Seybold Clinic physicians reviewed the results and found that misconceptions regarding postpartum depression persist, despite increased exposure and discussion in recent years.
  • Postpartum depression is a serious mood disorder, which may affect the mothers ability to care for herself and her newborn, said Deepali Patni, M.D., F.A.C.O.G.

Perinatal depression: RNAO best practice guideline recommends routine screening

Retrieved on: 
Thursday, October 11, 2018
RTT, Midwifery, Women's health, Human reproduction, Health, Depression, Psychiatric diagnosis, Sexual reproduction, Childbirth, Major depressive disorder, Pregnancy, Postpartum period

RNAO's Assessment and Interventions for Perinatal Depression (second edition) best practice guideline (BPG) was released today at a press conference in Toronto.

Key Points: 
  • RNAO's Assessment and Interventions for Perinatal Depression (second edition) best practice guideline (BPG) was released today at a press conference in Toronto.
  • Perinatal depression is a term used to describe depression that can occur during pregnancy or up to one year following childbirth.
  • It is estimated that between 10 and 14 per cent of those within that population group in Canada will develop perinatal depression.
  • Given the risks, the guideline recommends that routine screening be integrated into prenatal and postpartum care.